Henrik Hjorth-Hansen, md phd
St. Olavs Hospital · Norwegian University of Science and Technology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Henrik Hjorth-Hansen, md phd as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03831776 · Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From DiagnosisSt. Olavs Hospital · completed · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT01725204 · Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid LeukemiaNorwegian University of Science and Technology · completed · Leukemia, Myeloid, Chronic-Phase · study chair
- Ph2NCT00852566 · Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaNorwegian University of Science and Technology · completed · Chronic Myeloid Leukemia · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in chronic myeloid leukemia.